Albumin-bilirubin (ALBI) Score at Admission Predicts Possible Outcomes in Patients with Acute-on-chronic Liver Failure

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Jun 15

PMID 28614241

Citations 34

Authors

Bo Chen

Sha Lin

Affiliations

Soon will be listed here.

Abstract

The albumin-bilirubin (ALBI) score is a new model for assessing the severity of liver dysfunction. The purpose of the present study is to investigate the prognostic value of the ALBI score in predicting the 3-month outcome of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (AoCLF).This study included 84 patients with HBV-AoCLF, 56 chronic hepatitis B (CHB) patients, and 48 healthy controls (HCs). The virological parameters and biochemical examination of blood were obtained after 12 hours of fasting. The follow-up of AoCLF patients lasted for at least 3 months, and the relationships between the prognosis and ALBI score were analyzed.A significantly higher ALBI score was detected in AoCLF patients than in the HC and CHB groups (both P = .001). The ALBI score was positively correlated with the model of the end-stage liver disease (MELD) score and Child-Pugh score. Moreover, ALBI scores were higher among non-survivors than survivors in AoCLF patients. Multivariate analysis suggested that both the ALBI and MELD scores were independent predictors of the 3-month mortality in AoCLF patients (P < .001).A high ALBI score measured at admission may be used as a predictor for the 3-month mortality rate in patients with HBV-AoCLF.

Citing Articles

A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure.

Ding W, Shen J, Zhang L, Shao J, Bian Z, Xue H Front Med (Lausanne). 2025; 11():1406275.

PMID: 39835109 PMC: 11744009. DOI: 10.3389/fmed.2024.1406275.

Albumin-bilirubin score in non-malignant liver and other diseases.

Zhang L, Chen L, Yang W, Hu B World J Gastroenterol. 2024; 30(41):4481-4483.

PMID: 39534421 PMC: 11551678. DOI: 10.3748/wjg.v30.i41.4481.

The utility of albumin-bilirubin score in patients with intrahepatic cholestasis of pregnancy: a retrospective comparative study.

Ozkavak O, Tanacan A, Haksever M, Sahin R, Serbetci H, Okutucu G Rev Assoc Med Bras (1992). 2024; 70(11):e20240860.

PMID: 39475920 PMC: 11509178. DOI: 10.1590/1806-9282.20240860.

Development and Validation of a New Prognostic Model for Predicting Survival Outcomes in Patients with Acute-on-chronic Liver Failure.

Li W, Liu W, Rong Y, Li D, Zhu B, Yang S J Clin Transl Hepatol. 2024; 12(10):834-844.

PMID: 39440220 PMC: 11491505. DOI: 10.14218/JCTH.2024.00316.

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.

Storandt M, Zemla T, Patell K, Naleid N, Gile J, Tran N Oncologist. 2024; 29(11):986-996.

PMID: 38979643 PMC: 11546648. DOI: 10.1093/oncolo/oyae142.

References

Lopez-Velazquez J, Chavez-Tapia N, Ponciano-Rodriguez G, Sanchez-Valle V, Caldwell S, Uribe M . Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. Ann Hepatol. 2014; 13(1):98-104. View

Freeman Jr R, Wiesner R, Harper A, McDiarmid S, Lake J, Edwards E . The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002; 8(9):851-8. DOI: 10.1053/jlts.2002.35927. View

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

Wang J, Ma K, Han M, Guo W, Huang J, Yang D . Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int. 2015; 8(1):64-71. DOI: 10.1007/s12072-013-9485-5. View

Sarin S, Kumar A, Almeida J, Chawla Y, Fan S, Garg H . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009; 3(1):269-82. PMC: 2712314. DOI: 10.1007/s12072-008-9106-x. View

Durand F, Valla D . Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005; 42 Suppl(1):S100-7. DOI: 10.1016/j.jhep.2004.11.015. View

Lai J, Yan Y, Mai L, Zheng Y, Gan W, Ke W . Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure. Hepatobiliary Pancreat Dis Int. 2013; 12(2):154-9. DOI: 10.1016/s1499-3872(13)60025-9. View

Jalan R, Williams R . Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002; 20(3):252-61. DOI: 10.1159/000047017. View

Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

10.

Chan A, Chan R, Wong G, Wong V, Choi P, Chan H . New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. J Gastroenterol Hepatol. 2015; 30(9):1391-6. DOI: 10.1111/jgh.12938. View

11.

Chen R, Cai Y, Wu J, Wang X, Song M, Wang Y . Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat. 2016; 24(3):238-245. DOI: 10.1111/jvh.12638. View

12.

Durand F, Valla D . Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008; 28(1):110-22. DOI: 10.1055/s-2008-1040325. View

13.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

14.

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T . Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015; 33(6):1257-62. DOI: 10.1007/s10637-015-0292-9. View

15.

Moreau R, Arroyo V . Acute-on-chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2014; 13(5):836-41. DOI: 10.1016/j.cgh.2014.02.027. View

16.

Ma X, Zhou J, Gao X, Tian L, Wu J, Zhang C . Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin Chim Acta. 2016; 462:15-22. DOI: 10.1016/j.cca.2016.08.005. View

17.

Pinato D, Sharma R, Allara E, Yen C, Arizumi T, Kubota K . The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2016; 66(2):338-346. DOI: 10.1016/j.jhep.2016.09.008. View

18.

Toyoda H, Lai P, OBeirne J, Chong C, Berhane S, Reeves H . Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer. 2016; 114(7):744-50. PMC: 4984858. DOI: 10.1038/bjc.2016.33. View